These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 28315555)

  • 21. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.
    O'Regan KN; Jagannathan JP; Ramaiya N; Hodi FS
    AJR Am J Roentgenol; 2011 Aug; 197(2):W241-6. PubMed ID: 21785048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy Toxicities.
    Sanchez K; Page DB; Urba W
    Surg Oncol Clin N Am; 2019 Jul; 28(3):387-401. PubMed ID: 31079795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.
    Ouwerkerk J; Boers-Doets C
    Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer immunotherapy and the management of side effects.
    Mahalingam P; Newsom-Davis T
    Clin Med (Lond); 2023 Jan; 23(1):56-60. PubMed ID: 36697001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.
    Eigentler TK; Hassel JC; Berking C; Aberle J; Bachmann O; Grünwald V; Kähler KC; Loquai C; Reinmuth N; Steins M; Zimmer L; Sendl A; Gutzmer R
    Cancer Treat Rev; 2016 Apr; 45():7-18. PubMed ID: 26922661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immune-related adverse events of immune checkpoint inhibitors].
    Tadano H; Torigoe T
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):102-108. PubMed ID: 28603200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Caring for Patients Treated With Checkpoint Inhibitors for the Treatment of Metastatic Merkel Cell Carcinoma.
    Rubin KM; Hoffner B; Bullock AC
    Semin Oncol Nurs; 2019 Oct; 35(5):150924. PubMed ID: 31514991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019).
    Majem M; García-Martínez E; Martinez M; Muñoz-Couselo E; Rodriguez-Abreu D; Alvarez R; Arance A; Berrocal A; de la Cruz-Merino L; Lopez-Martin JA
    Clin Transl Oncol; 2020 Feb; 22(2):213-222. PubMed ID: 31993963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
    Martins F; Sykiotis GP; Maillard M; Fraga M; Ribi C; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
    Lancet Oncol; 2019 Jan; 20(1):e54-e64. PubMed ID: 30614479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities].
    Moura B; Homicsko K; Berthod G; Cerottini JP; Guggisberg D; Gaide O; Maillard MH; Michielin O
    Rev Med Suisse; 2015 May; 11(475):1108, 1110-4. PubMed ID: 26152085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety of anti PD-1 therapeutics for the treatment of melanoma.
    Ramelyte E; Schindler SA; Dummer R
    Expert Opin Drug Saf; 2017 Jan; 16(1):41-53. PubMed ID: 27737598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Management of immune-related adverse events during treatment with immune checkpoint inhibitors].
    Queirolo P; Spagnolo F
    Recenti Prog Med; 2016 Aug; 107(8):407-13. PubMed ID: 27571555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
    Camacho LH
    Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of immunotherapy toxicities in older adults.
    Bhandari S; Gill AS; Perez CA; Jain D
    Semin Oncol; 2018 Aug; 45(4):226-231. PubMed ID: 30446167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune Checkpoint Inhibitor Therapy: Key Principles When Educating Patients.
    Wood LS; Moldawer NP; Lewis C
    Clin J Oncol Nurs; 2019 Jun; 23(3):271-280. PubMed ID: 31099804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions.
    Atkins M
    Semin Oncol; 2015 Dec; 42 Suppl 3():S12-9. PubMed ID: 26598055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ipilimumab for advanced melanoma: a nursing perspective.
    Ledezma B
    Oncol Nurs Forum; 2009 Jan; 36(1):97-104. PubMed ID: 19136343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects.
    Lombardi A; Mondelli MU
    Aliment Pharmacol Ther; 2019 Oct; 50(8):872-884. PubMed ID: 31378985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
    Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
    Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.